VanEck Pharmaceutical ETF News

The start of 2024 has been weak for the global stock market after a blockbuster 2023. Still, a few corners of the stock market are outperforming, pushing ETFs to new 52-week highs.

After underperforming in 2023, the healthcare sector seems to be back on track at the start of the New Year. Healthcare generally outperforms during periods of low growth and high uncertainty.

Launched on 12/20/2011, the VanEck Pharmaceutical ETF (PPH) is a passively managed exchange traded fund designed to provide a broad exposure to the Healthcare - Pharma segment of the equity market.

The XBI has been climbing this month. On Tuesday it jumped 5.4% to close at $70.91.

Many industry bigwigs reported solid results, with some beating on earnings or revenues or both.

If you're interested in broad exposure to the Healthcare - Pharma segment of the equity market, look no further than the VanEck Pharmaceutical ETF (PPH), a passively managed exchange traded fund launc

VanEck Pharmaceutical ETF has had the strongest one-year performance of four major pharmaceutical ETF competitors due to its unique mix of Novo Nordisk, Eli Lilly, and Johnson & Johnson. Eli Lilly, PP

Eli Lilly is a mega-cap stock in the Health Care sector that has performed well in 2023, and it's the top holding in the VanEck Pharmaceutical ETF. I have a buy rating on the low-cost and style & geog

According to the latest CDC National Diabetes Statistics Report, more than 37 million people have diabetes in the U.S., or 11.3% of the population. The statistics for obesity are also dismal, as the W

Ozempic commercials are, at this point, ubiquitous and while that's an anecdotal example, it also represents confirmation that obesity drugs are the next big thing in the pharmaceuticals industry.

The VanEck Pharmaceutical ETF (PPH) was launched on 12/20/2011, and is a passively managed exchange traded fund designed to offer broad exposure to the Healthcare - Pharma segment of the equity market

Wall Street delivered a mixed performance last week.

Second-quarter earnings beat ratio of 86.6% and revenue beat ratio of 84.9% for the healthcare sector are impressive.

Value-focused investing comes to rescue if high-growth sectors fail for some reasons.

Investors seeking momentum may have VanEck Pharmaceutical ETF PPH on radar now. The fund recently hit a new 52-week high.